SRSF2 is altered in 12.04% of acute myeloid leukemia patients [3].

SRSF2 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain SRSF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

SRSF2 is altered in 11.78% of myelodysplastic syndromes patients [3].

SRSF2 is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain SRSF2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

SRSF2 is altered in 10.84% of secondary acute myeloid leukemia patients [3].

SRSF2 is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain SRSF2 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

SRSF2 is altered in 39.57% of chronic myelomonocytic leukemia patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SRSF2 is altered in 31.69% of myelodysplastic/myeloproliferative neoplasm patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SRSF2 is altered in 20.8% of myelodysplastic syndrome with excess blasts-2 patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

SRSF2 is altered in 18.75% of myelodysplastic/myeloproliferative neoplasm, unclassifiable patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

SRSF2 is altered in 11.85% of myeloid neoplasm patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

SRSF2 is altered in 10.84% of therapy-related acute myeloid leukemia patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

SRSF2 is altered in 6.02% of myelofibrosis patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains SRSF2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

SRSF2 is altered in 4.23% of therapy-related myelodysplastic syndrome patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

SRSF2 is altered in 0.46% of multiple myeloma patients [3].

SRSF2 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains SRSF2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [4].

SRSF2 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

SRSF2 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains SRSF2 status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].